Truist lowered the firm’s price target on Iqvia (IQV) to $245 from $290 and keeps a Buy rating on the shares. The firm is updating its model after the re-segmentation following the company’s Q4 earnings while also reducing its assumed forward EBITDA multiple to 13x from 14x to reflect the near-term AI disruption overhang, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $174 from $245 at TD Cowen
- IQVIA: Solid 2026 Outlook but AI Disruption Risks Justify Hold Rating and Lowered Valuation
- Iqvia price target lowered to $240 from $265 at Morgan Stanley
- Iqvia announces collaboration with Duke Clinical Research Institute
- IQVIA Holdings Earnings Call Signals AI-Driven Growth